Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Denali Therapeutics Inc (DNLI) COM USD0.01

Sell:$41.14 Buy:$41.19 Change: $0.22 (0.54%)
NASDAQ:0.37%
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:$41.14
Buy:$41.19
Change: $0.22 (0.54%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
Sell:$41.14
Buy:$41.19
Change: $0.22 (0.54%)
Market closed |  Prices as at close on 23 October 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.

Contact details

Address:
161 Oyster Point Blvd
SOUTH SAN FRANCISCO
94080-1910
United States
Telephone:
+1 (650) 8668548
Website:
https://www.denalitherapeutics.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DNLI
ISIN:
US24823R1059
Market cap:
$4.20 billion
Shares in issue:
105.98 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Vicki Sato
    Independent Chairman of the Board
  • Ryan Watts
    President, Chief Executive Officer, Co-Founder, Director
  • Alexander Schuth
    Co-Founder, Chief Operating Officer, Secretary
  • Steve Krognes
    Chief Financial Officer, Treasurer
  • Carole Ho
    Chief Medical Officer, Head of Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.